Skip to main content
Published: 2019-08-19 17:03 | Updated: 2019-08-20 09:26

Increased risk of psychiatric disorders in children with IBD

Drs Agnieszka Butwicka and Jonas Ludvigsson at the Department of Medical Epidemiology and Biostatistics. Credit: Gunilla Sonnebring.

Children with Inflammatory Bowel Disease (IBD) run a greater risk of psychiatric disorders, according to a new study from Karolinska Institutet in Sweden published in JAMA Pediatrics. The researchers claim that more psychological support and longer follow-up is needed for the children affected and their parents.

It is already known that adults with IBD (Ulcerative Colitis or Crohn’s Disease) run an increased risk of psychiatric disorders. Now a new study shows that children with IBD also run a higher risk of mental health problems.

More than 6,400 children with IBD, born between 1973 and 2013, were included in the study. Using population registers, the researchers compared the risk of psychiatric disorders later on in life with both healthy children from the general population and with the patients’ own siblings. By comparing the patients with their siblings, it was possible to take a large number of so-called confounders, such as socioeconomics, lifestyle and heredity into account, factors that are known to affect the risk of psychiatric disorders in children.

The higher risk applied to a number of psychiatric diagnoses

During an average follow-up period of 9 years, approximately 17 per cent of the children with IBD were given a psychiatric diagnosis compared with just under 12 per cent of the healthy children and about 10 per cent of the siblings. This means that the risk of psychiatric disorders was 1.6 times higher in children with IBD compared to Swedish children from general population. Likewise, the risk for the children with IBD was greater than for their siblings.

The higher risk applied to a number of psychiatric diagnoses such as depression, anxiety, eating disorders, personality disorders, ADHD and autism spectrum disorder. There was also a higher risk of suicide attempt after reaching adulthood.

”The study shows that children with IBD and their parents are in need of psychological support and longer follow-up,” says Agnieszka Butwicka, researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. “Special help could be offered to children who become ill at a young age and to children of parents with mental health problems.

The risk of mental health problems was greatest during the first year with IBD. The risk was particularly high for children who were diagnosed with IBD before the age of 6 years and for children of parents with psychiatric disorders.

Observation study

The study is an observation study that cannot identify causality with certainty. However, according to the researchers, the results do indicate that IBD contributes to mental health problems. 

”Because the risk for these children is higher compared with their own siblings, it is likely that it is IBD affecting their mental health rather than other factors such as socioeconomics, lifestyle or heredity in the family,” says Jonas F. Ludvigsson, professor at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.

The research was conducted with funding from Fredrik och Ingrid Thurings Stiftelse, Mag-Tarmfonden, the Mjölkdroppen foundation, the Jane and Dan Olsson foundation, the Swedish Cancer Society, the Swedish Foundation for Strategic Research, the Swedish medical association, the Strategic Research Programme in Neuroscience (StratNeuro) at Karolinska Institutet, the Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM), the Swedish Research Council, and Stockholm County Council.

Co-author Henrik Larsson has served as a speaker for Eli Lilly and Shire and has received research grants from Shire; all outside the submitted work. Jonas Halfvarson received consulting/lecture fees from Abbvie, Celgene, Ferring, Hospira, Janssen, Medivir, MSD, Pfizer, Prometheus, Renapharma Vifor, Sandoz, Shire, Takeda, and Tillotts Pharma and research grants from Janssen, MSD and Takeda. Ola Olén has been principal investigator for projects at Karolinska Institutet partly financed by investigator-initiated grants from Janssen and Pfizer and has received fees for lectures and participation on advisory boards from Janssen, Ferring and Takeda. Jonas F. Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBREG), which has received funding from Janssen Corporation.

Publication 

“Childhood-onset inflammatory bowel disease and risk of psychiatric disorders and suicide attempt – a nationwide cohort study with sibling comparisons”.

Agnieszka Butwicka, Ola Olén, Henrik Larsson, Jonas Halfvarson, Catarina Almqvist, Paul Lichtenstein, Eva Serlachius, Louise Frisén, Jonas F. Ludvigsson.

JAMA Pediatrics, online 19 August 2019. doi:10.1001/jamapediatrics.2019.2662.